Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
Metrics: PDF 1445 views | HTML 2463 views | ?
Sabrina Lagniau1,2, Kevin Lamote1,2, Jan P. van Meerbeeck2,3,* and Karim Y. Vermaelen1,2,*
1Tumor Immunology Laboratory, Department of Respiratory Medicine, Ghent University Hospital, 9000 Ghent, Belgium
2Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium
3Thoracic Oncology/MOCA, Antwerp University Hospital, 2650 Edegem, Belgium
*Joint senior authors
Karim Y. Vermaelen, email: Karim.firstname.lastname@example.org
Keywords: mesothelioma, biomarkers
Received: November 24, 2016 Accepted: May 01, 2017 Published: May 17, 2017
Early diagnosis of malignant pleural mesothelioma (MPM) is a challenge for clinicians. The disease is usually detected in an advanced stage which precludes curative treatment. We assume that only new and non-invasive biomarkers allowing earlier detection will result in better patient management and outcome. Many efforts have already been made to find suitable biomarkers in blood and pleural effusions, but have not yet resulted in a valid and reproducible diagnostic one. In this review, we will highlight the strengths and shortcomings of blood and fluid based biomarkers and highlight the potential of breath analysis as a non-invasive screening tool for MPM. This method seems very promising in the early detection of diverse malignancies, because exhaled breath contains valuable information on cell and tissue metabolism. Research that focuses on breath biomarkers in MPM is in its early days, but the few studies that have been performed show promising results. We believe a breathomics-based biomarker approach should be further explored to improve the follow-up and management of asbestos exposed individuals.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.